EU ruling on $25 billion Abbott, St. Jude deal due by November 9
- Wall Street rally continues as laggards advance
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Traders gather at the booth that trades Abbott Laboratories on the floor of the New York Stock Exchange, December 10, 2012. REUTERS/Brendan McDermid/File Photo
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
BRUSSELS (Reuters) - EU antitrust regulators will decide by Nov. 9 whether to clear U.S. pharmaceuticals company Abbott Laboratories' (NYSE: ABT) $25-billion bid for St. Jude Medical Inc (NYSE: STJ) aimed at helping it better compete with bigger rivals.
Abbott sought the European Commission's approval for the deal on Oct. 3, according to a filing on the EU competition enforcer's website on Tuesday.
The Commission can either clear the deal with or without concessions or it can open a full-scale investigation if it has serious concerns. The majority of pharmaceutical mergers get the green light with or without conditions in the EU's preliminary review.
Abbott's takeover bid comes as medical equipment makers come under pressure to offer a wider portfolio of products to hospital customers, which have gained more negotiating power on pricing after a wave of mergers.
(Reporting by Foo Yun Chee; Editing by Mark Potter)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- St. Jude Medical Announces Fourth Quarter Dividend
- U.S. agency concerned about destroyed, lost phones in VW probe
- Lebanese government must be formed as soon as possible: Hezbollah